The new safety mandate driving AI-ready pharmacovigilance
Regulatory expectations in the drug safety industry have evolved faster in the past five years than in the previous two…
20 Jan 2026
When trillion‑member libraries meet physics: what diversity really means
Dr Karsten Eastman, CEO, Sethera Therapeutics, highlights the challenges around ‘true’ diversification in DNA libraries. In drug discovery, big numbers for screening campaigns are loved. Trillions of molecules! 1020‑member libraries!…
16 Dec 2025
The hidden crisis in regenerative medicine
Dr Tommy Rhee, CEO of RheeGen, outlines how FDA crackdowns have revealed dangerous and unethical tissue sourcing practices: Two decades ago, regenerative medicine started out with an extraordinary scientific promise.…
18 Nov 2025
FDA inspection reveals critical supply chain vulnerabilities
When US Food and Drug Administration (FDA) inspectors arrived unannounced at Hetero Labs' warehouse facility in Visakhapatnam, India, on 19 September , they documented conditions that would result in a…
18 Nov 2025
Real-time data: how to gain an edge amid clinical services consolidation
The pharmaceutical services industry is undergoing both innovation and consolidation – trends that are redefining competition and opening new strategic fronts for clinical technology vendors and contract research organizations (CROs).…
29 Sep 2025
The dangerous second life of medical waste
Beyond the more apparent environmental challenges of rising medical waste from at-home injectables like Glucagon-like peptide-1 (GLP-1) agonists, pharmaceutical companies are grappling with a quieter but equally urgent issue: the…
29 Apr 2024
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding
US lawmakers have added more Chinese biotech and medtech companies to the list of firms posing national security risks that they are seeking to prevent doing business with the US.…